Ganaxolone for treating seizures caused by CDKL5 deficiency disorder in people 2 years and over

Ganaxolone (Ztalmy, Orion and Marinus) is indicated for the 'adjunctive treatment of epileptic seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients 2 to 17 years of age. Ztalmy may be continued in patients 18 years of age and older'.

The dosage schedule is available in the summary of product characteristics for ganaxolone.

The list price for ganaxolone is confidential and cannot be reported here.

The company has a commercial arrangement, which would have applied if ganaxolone had been recommended.